Get the Stockscreener App
4.01
3.08%
0.12
After Hours:
4.02
0.010
+0.25%
Trisalus Life Sciences Inc stock is traded at $4.01, with a volume of 153.90K.
It is up +3.08% in the last 24 hours and down -26.01% over the past month.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
See More
Previous Close:
$3.89
Open:
$3.95
24h Volume:
153.90K
Relative Volume:
0.80
Market Cap:
$245.84M
Revenue:
$45.15M
Net Income/Loss:
$-39.23M
P/E Ratio:
-2.1925
EPS:
-1.829
Net Cash Flow:
$-18.93M
1W Performance:
+4.16%
1M Performance:
-26.01%
6M Performance:
-15.76%
1Y Performance:
-29.03%
1-Day Range:
$3.91
$4.09
1-Week Range:
$3.70
$4.09
52-Week Range:
$3.42
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.01 | 238.48M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
Momentum Shift: Does TriSalus Life Sciences Inc have pricing power2026 Top Gainers & Technical Confirmation Alerts - baoquankhu1.vn
What is Northland Securities' Estimate for TLSI Q1 Earnings? - MarketBeat
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock - Defense World
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $61,384.40 in Stock - Defense World
Weekly Earnings: Can TriSalus Life Sciences Inc Equity Warrant keep up with sector leadersMarket Risk Analysis & Fast Exit and Entry Trade Guides - baoquankhu1.vn
TriSalus Life Sciences launches proposed public stock offering - MSN
Aug Movers: Is TriSalus Life Sciences Inc Equity Warrant a top pick in the sector2026 Price Targets & Community Consensus Trade Signals - baoquankhu1.vn
RSI Check: Is TriSalus Life Sciences Inc Equity Warrant forming a bullish divergenceMarket Volume Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
Top TriSalus Executives Make Major Moves With Insider Stock Sales - TipRanks
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $61,384.40 in Stock - MarketBeat
Szela, CEO of TriSalus, sells $79k in TLSI stock By Investing.com - Investing.com India
Szela, CEO of TriSalus, sells $79k in TLSI stock - Investing.com
TriSalus Life Sciences (TLSI) chief regulatory officer sells $14509 in stock - Investing.com
Devlin Jodi, TriSalus Life Sciences chief, sells $13k in TLSI stock - Investing.com Canada
Trisalus Life Sciences’ CCO Marshak sells $14k in TLSI stock - Investing.com India
TriSalus Life Sciences chief of research Cox sells $13k in TLSI stock - Investing.com
TriSalus (TLSI) executive sells 3,207 shares to satisfy RSU tax withholding - Stock Titan
TriSalus (TLSI) Chief of Research has 3,184 shares sold for tax withholding - Stock Titan
TriSalus (TLSI) CCO logs small tax-related share disposals, retains over 110K shares - Stock Titan
TriSalus Life Sciences (TLSI) CRO sells shares for taxes - Stock Titan
TriSalus (TLSI) CEO Szela disposes 20,302 shares for tax withholding - Stock Titan
TriSalus publishes preclinical data on drug delivery technology By Investing.com - Investing.com South Africa
Should I invest in TriSalus Life Sciences Inc before earningsWall Street Watch & Technical Buy Zone Confirmations - baoquankhu1.vn
TriSalus publishes preclinical data on drug delivery technology - Investing.com
Animal study from TriSalus pumps more immune drug into liver tumors in models - Stock Titan
Update Recap: What is the dividend yield of TriSalus Life Sciences Inc Equity WarrantRate Hike & Precise Entry and Exit Recommendations - baoquankhu1.vn
Published on: 2026-03-18 18:04:21 - baoquankhu1.vn
Analysis Recap: Is TriSalus Life Sciences Inc Equity Warrant benefiting from innovation trends2026 Key Lessons & Capital Efficiency Focused Ideas - baoquankhu1.vn
Canaccord lowers its price target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and maintains a buy rating - MSN
Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating - Insider Monkey
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
TriSalus Life Sciences Signals Confident Growth Path - TipRanks
11 Fastest Growing Penny Stocks to Buy Right Now - Insider Monkey
TLSIW Stock Price, News & Analysis - Stock Titan
Research Analysts Issue Forecasts for TLSI Q1 Earnings - MarketBeat
Canaccord Genuity Group Has Lowered Expectations for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price - Defense World
TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Canaccord Genuity Group Issues Pessimistic Forecast for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price - MarketBeat
Jones Trading reiterates Buy on TriSalus Life Sciences stock after earnings By Investing.com - Investing.com South Africa
Jones Trading reiterates Buy on TriSalus Life Sciences stock after earnings - Investing.com
TriSalus Life Sciences Q4 Earnings Call Highlights - Yahoo Finance
Boston Scientific to buy Penumbra in $14.5 billion deal - AOL.com
TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio - MSN
Earnings call transcript: TriSalus Life Sciences sees 60% Q4 revenue rise - Investing.com
TriSalus (TLSI) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: TriSalus Life Sciences sees 60% Q4 revenue rise By Investing.com - Investing.com South Africa
TriSalus Life Sciences (NASDAQ:TLSI) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
TriSalus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance - Bluefield Daily Telegraph
Earnings Summary: TriSalus Life Sciences Q4 - Benzinga
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):